A number of CMS patients and families with children who use 3,4 DAP have been concerned over recent changes to both the supply and branding of this drug.
To download a factsheet issued by the Myasthenia Gravis Association on 30 July 2010, click here.
To view a report on the issue from the NHS North East Advisory Group, click here.
To read the Sunday Express story on this from 5th September 2010, click here.